Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Second Skin Cancers

Annika Nelde, Daniel Johannes Kowalewski, Linus Backert, Lothar Kanz, Helmut R. Salih, MD, Hans-Georg Rammensee, Stefan Stevanovic, Juliane Sarah Walz

Blood (2017) 130 (Supplement 1): 5329.

https://doi.org/10.1182/blood.V130.Suppl_1.5329.5329

Published: 2017

Journal Articles

HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy

Annika Nelde, Daniel J. Kowalewski, Linus Backert, Heiko Schuster, Lothar Kanz, MD, Helmut R. Salih, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 3234.

https://doi.org/10.1182/blood.V128.22.3234.3234

Published: 2016

Journal Articles

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Linus Backert, Daniel J. Kowalewski, Simon D. Walz, Heiko Schuster, Claudia Berlin, Mirle Schemionek, PhD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Lothar Kanz, MD, Helmut R. Salih, MD, Katja Weisel, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 2169.

https://doi.org/10.1182/blood.V128.22.2169.2169

Published: 2016

Journal Articles

Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations

Sebastian P. Haen, MD, Daniel J. Kowalewski, Joerg Bernhardt, Linus Backert, Daniel Backes, Florian Dengler, Stefan Beckert, Ingmar Koenigsrainer, Hans-Georg Kopp, MD, Oliver Kohlbacher, Alfred Koenigsrainer, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Markus W. Loeffler, MD

Blood (2016) 128 (22): 862.

https://doi.org/10.1182/blood.V128.22.862.862

Published: 2016

Journal Articles

Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type

Sebastian P. Haen, MD, Daniel Johannes Kowalewski, Stefan Stevanovic, PhD, Linus Backert, Florian Dengler, Daniel Backes, Stefan Beckert, Wagner Silvia, Ingmar Koenigsrainer, Hans-Georg Kopp, MD, Oliver Kohlbacher, Alfred Koenigsrainer, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Markus W. Loeffler, MD

Blood (2015) 126 (23): 1027.

https://doi.org/10.1182/blood.V126.23.1027.1027

Published: 2015

Journal Articles

Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy

Daniel Johannes Kowalewski, Simon D. Walz, Linus Backert, Heiko Schuster, Susanne M. Rittig, MD, Katja C. Weisel, Helmut R Salih, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S Stickel, MD

Blood (2015) 126 (23): 3001.

https://doi.org/10.1182/blood.V126.23.3001.3001

Published: 2015

Journal Articles

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers

Juliane S Stickel, MD, Daniel Johannes Kowalewski, Heiko Schuster, Stefan Kahn, Linus Backert, Lothar Kanz, MD, Helmut R Salih, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD

Blood (2015) 126 (23): 1722.

https://doi.org/10.1182/blood.V126.23.1722.1722

Published: 2015

Journal Articles

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

Simon Walz, Juliane S. Stickel, Daniel Johannes Kowalewski, Heiko Schuster, Katja Weisel, Linus Backert, Stefan Kahn, Annika Nelde, Tatjana Stroh, Martin Handel, Oliver Kohlbacher, Lothar Kanz, Helmut Rainer Salih, Hans-Georg Rammensee, Stefan Stevanović

Blood (2015) 126 (10): 1203–1213.

https://doi.org/10.1182/blood-2015-04-640532

Published: 2015

Includes: Supplemental data

Journal Articles

HLA Ligandome Profiling Identifies a Novel Category of Pathophysiologically Relevant CLL Associated Antigens

Daniel J. Kowalewski, Heiko Schuster, Claudia Berlin, Stefan Kahn, Linus Backert, Lothar Kanz, MD, Helmut R. Salih, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2014) 124 (21): 715.

https://doi.org/10.1182/blood.V124.21.715.715

Published: 2014

NARROW

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Second Skin Cancers

HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations

Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type

Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

HLA Ligandome Profiling Identifies a Novel Category of Pathophysiologically Relevant CLL Associated Antigens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only